Oxytocin intranasal - Vyera Pharmaceuticals

Drug Profile

Oxytocin intranasal - Vyera Pharmaceuticals

Alternative Names: Syntocinon Nasal Spray; TUR 001

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Retrophin; Turing Pharmaceuticals; University of California, San Diego
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder; Lactation failure; Schizophrenia

Most Recent Events

  • 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals (Vyera Pharmaceuticals California Comprehensive Compliance Program, September 2017)
  • 15 Feb 2017 Discontinued - Clinical-Phase-Unknown for Schizophrenia (Adjunctive treatment) in USA (Intranasal)
  • 15 Feb 2017 Discontinued - Phase-II for Lactation failure in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top